Anyone taking phenelzine should inform their dentist before proceeding with dental surgery, and surgeon in any other contexts. Phenelzine has also been linked to vitamin B6 deficiency. Transaminases such as GABA-transaminase have been shown to be dependent upon vitamin B6 and may be involved in a potentially related process, since the phenelzine metabolite phenylethylidenehydrazine (PEH) is a GABA transaminase inhibitor. Both phenelzine and vitamin B6 are rendered inactive upon these reactions occurring. For this reason, it may be recommended to supplement with vitamin B6 while taking phenelzine. The pyridoxine form of B6 is recommended for supplementation, since this form has been shown to reduce hydrazine toxicity from phenelzine and, in contrast, the pyridoxal form has been shown to increase the toxicity of hydrazines. Research
Phenelzine showed promise in a phase II clinical trial from March 2020 in treating prostate cancer. Phenelzine has also been shown to have neuroprotective effects in animal models. History
Synthesis of phenelzine was first described by Emil Votoček and Otakar Leminger in 1932. See also
Phenylethylidenehydrazine
Hydrazine (antidepressant)
Isocarboxazid
Libby Zion Law (a case involving phenelzine and pethidine)
Monoamine oxidase inhibitor
Tranylcypromine

References
External links
"Phenelzine". Drug Information Portal. U.S. National Library of Medicine.
The host immune response involves cytotoxic (CD8-positive) T cells against infected B lymphocytes, resulting in enlarged, atypical lymphocytes (Downey cells).When the infection is acute (recent onset, instead of chronic), heterophile antibodies are produced.Cytomegalovirus, adenovirus and Toxoplasma gondii (toxoplasmosis) infections can cause symptoms similar to infectious mononucleosis, but a heterophile antibody test will test negative and differentiate those infections from infectious mononucleosis.Mononucleosis is sometimes accompanied by secondary cold agglutinin disease, an autoimmune disease in which abnormal circulating antibodies directed against red blood cells can lead to a form of autoimmune hemolytic anemia. The cold agglutinin detected is of anti-i specificity. Diagnosis
Diagnostic modalities for infectious mononucleosis include:

Persons age, with highest risk at 10 to 30 years. Medical history, such as close contact with other people with infectious mononucleosis, and the presence and time of onset of "mononucleosis-like symptoms" such as fever and sore throat. Physical examination, including palpation of any enlarged lymph nodes in the neck, or enlarged spleen. The heterophile antibody test is a screening test that gives results within a day, but has significantly less than full sensitivity (70–92%) in the first two weeks after clinical symptoms begin. Serological tests take longer time than the heterophile antibody test, but are more accurate. Physical examination
The presence of an enlarged spleen, and swollen posterior cervical, axillary, and inguinal lymph nodes are the most useful to suspect a diagnosis of infectious mononucleosis.